Feasibility of Personal Sound Amplification Products in Patients With Moderate Hearing Loss: A Pilot Study
Clinical and Experimental Otorhinolaryngology · 01.02.2022 · 15 (1) · 60-68
DOI: 10.21053/ceo.2020.02313 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Experimental Otorhinolaryngology, erschienen am 01.02.2022. Verfasst von Ga-Young Kim und 5 weiteren Autor:innen. Beteiligte Einrichtung: Hearing Research Laboratory, Samsung Medical Center, Seoul, Korea. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0). Gefördert von: Ministry of Health and Welfare.
Abstract (Originalsprache)
Objectives
This study was conducted to investigate the electroacoustic characteristics of personal sound amplification products (PSAPs), to identify whether PSAPs provide adequate gain and output for three common hearing loss (HL) configurations, and to compare the benefits of a representative PSAP (RPSAP) and a conventional hearing aid (HA) for clinical hearing outcomes as a pilot study.
Methods
The study comprised three phases: electroacoustic analysis, simulated real-ear measurements (REMs), and clinical hearing experiments. Electroacoustic analysis and simulated REMs were performed for three basic PSAPs (BeethoSOL, EarJJang, and Geniesori2) and three high-end PSAPs (Hearing Able, Olive Smart Ear, and SoriIn) using the Aurical Hearing Instrument Test box with a 2-mL coupler. Four electroacoustic characteristics (maximum output sound pressure level at 90 dB SPL, frequency range, equivalent input noise, and total harmonic distortion) were investigated. By simulated REMs, appropriate levels of the six PSAPs for three common HL configurations (mild-to-moderate high-frequency HL, moderate to moderately severe sloping HL, and moderate flat HL) were determined. Clinical experiments compared the performance of RPSAP to HA, both of which were fitted by audiologists using REMs. Clinical experiments were administered using functional gain, a word recognition test, and the Korean version of the Hearing in Noise Test in six participants with bilateral moderate sensorineural HL.
Results
The two high-end devices met all tolerances. One basic and two high-end PSAPs showed appropriate levels for three common HL configurations. In the clinical experiments, the RPSAP showed better performance than unaided, but slightly worse than HA under all test conditions.
Conclusion
Certain PSAPs met all specified tolerances for electroacoustic analysis and approximated prescriptive targets in well-controlled laboratory conditions. The pilot clinical experiments explored the possibility that the RPSAP could serve as a hearing assistive device for patients with moderate HL.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Hearing Research Laboratory, Samsung Medical Center, Seoul, Korea.
- Department of Otorhinolaryngology-Head and Neck Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Förderung
- Ministry of Health and Welfare
Zitieren
APA
Kim, G. Y., Kim, J. S., Jo, M., Seol, H. Y., Cho, Y. S., & Moon, I. J. (2022). Feasibility of Personal Sound Amplification Products in Patients With Moderate Hearing Loss: A Pilot Study. Clinical and Experimental Otorhinolaryngology, 15(1), 60-68. https://doi.org/10.21053/ceo.2020.02313
Vancouver
Kim GY, Kim JS, Jo M, Seol HY, Cho YS, Moon IJ. Feasibility of Personal Sound Amplification Products in Patients With Moderate Hearing Loss: A Pilot Study. Clinical and Experimental Otorhinolaryngology. 2022;15(1):60-68. doi:10.21053/ceo.2020.02313
BibTeX
@article{Kim2022,
author = {Kim, Ga-Young and Kim, Jong Sei and Jo, Mini and Seol, Hye Yoon and Cho, Young Sang and Moon, Il Joon},
title = {Feasibility of Personal Sound Amplification Products in Patients With Moderate Hearing Loss: A Pilot Study},
journal = {Clinical and Experimental Otorhinolaryngology},
year = {2022},
volume = {15},
number = {1},
pages = {60--68},
doi = {10.21053/ceo.2020.02313}
}
EUVIMED